ResearcherIRCCS Ospedale San RaffaeleNo recent work listed
Vito Lampasona
Matched on ORCID iD 0000-0001-5162-8445; OpenAlex author ID A5058744766. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2016: 1 paper · 2017: none · 2018: 2 papers
Papers 3
- Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
- No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Last author DOI 10.3233/cbm-181218↗
- (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniela Liberati · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Valentina Pasquale · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Erica Dugnani · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Gianpaolo Balzano · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Massimo Falconi · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Michele Reni · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Lorenzo Piemonti · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Claudio Doglioni · 2 shared papers, 2016–2018 · strength 0.12
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Stefano Cereda · 1 shared paper, 2016 · strength 0.05
- Carmen Belli · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.